25.12
Oral Hipoglisemik İlaçlar: Glinidler
Repaglinid (Prandin) ve Nateglinid (Starlix), glinidler olarak bilinir, ATP'ye duyarlı potasyum kanallarını (KATP kanalı) kapatarak pankreas β hücrele…
Glinidler, KATP kanallarını inhibe ederek ve potasyum akışını kontrol ederek β hücrelerden insülin salınımını tetikleyen insülin sekretagoglarıdır.
Sülfonilüreler ile iki bağlanma bölgesini ve bir benzersiz bağlanma bölgesini paylaşırlar.
Bir ilaç olan repaglinid, dört ila yedi saat süren daha kısa etkilerle hızlı bir etki başlangıcına sahiptir.
Yemeklerden önce alındığında tokluk glikoz artışlarını etkili bir şekilde kontrol eder.
Repaglinid, böbrek yetmezliği olan hastalarda ve yaşlılarda kullanılabilir. Bağımsız bir tedavi olabilir veya biguanidlerle kombine edilebilir.
Kükürt içermediği için şiddetli kükürt veya sülfonilüre alerjisi olan tip 2 diyabetik hastalarda kullanılabilir.
Başka bir ajan olan nateglinid, insülin sekresyonunu diğer hipoglisemik ajanlara göre daha hızlı ancak daha az sürekli etki ile uyarır.
Bu ilaçlar, yemeklerin gecikmesi, atlanması veya karbonhidrat oranının düşük olması durumunda hipoglisemik risk de dahil olmak üzere olumsuz etkiler gösterir.
View the full transcript and gain access to JoVE Core videos
Q1: How do glinides work to lower blood glucose in type 2 diabetes?
Glinides are insulin secretagogues that trigger insulin release from pancreatic β cells by inhibiting ATP-sensitive potassium channels (KATP channels) and controlling potassium efflux. They share two binding sites with sulfonylureas and possess one unique binding site, enabling overlapping yet distinct mechanisms of action for glucose control.
Q2: What are the key differences between repaglinide and nateglinide?
Repaglinide has a rapid onset with a 4-7 hour duration, effectively controlling postprandial glucose spikes when taken before meals. Nateglinide stimulates insulin secretion more rapidly but with less sustained action than other agents, potentially causing fewer hypoglycemic episodes while maintaining similar secondary failure rates.
Q3: When should glinides be taken, and why is meal timing important?
Glinides should be taken shortly before meals to effectively manage post-meal glucose spikes. Hypoglycemia risk increases significantly if meals are delayed, skipped, or low in carbohydrates, making proper meal timing and composition critical for safe and effective use of these agents.
Q4: Which patients are suitable candidates for repaglinide therapy?
Repaglinide is suitable for elderly patients and those with renal impairment, as it is primarily metabolized by the liver with minimal kidney involvement. It can also be used in type 2 diabetic patients with severe sulfur or sulfonylurea allergies since it lacks sulfur, and can be combined with biguanides.
Q5: What is the primary adverse effect of glinides, and how does it develop?
The major adverse effect of glinides is hypoglycemia, which develops when insulin secretion occurs without adequate carbohydrate intake. Risk increases if meals are delayed, skipped, or contain insufficient carbohydrates, making patient education about meal timing and composition essential for safe therapy.
Q6: How are repaglinide and nateglinide metabolized, and what clinical implications does this have?
Repaglinide is rapidly absorbed, reaching peak blood levels within an hour and is mainly metabolized by the liver with minimal kidney processing. Nateglinide is metabolized primarily by hepatic enzymes and should be used cautiously in patients with liver insufficiency, as hepatic impairment can alter drug metabolism.
Q7: Can drug interactions affect glinide effectiveness, and what should clinicians monitor?
Yes, certain drugs may enhance glinide action by altering metabolism or displacing them from plasma protein-binding sites, increasing hypoglycemia risk. Conversely, some medications may reduce the glucose-lowering effect of nateglinide. Clinicians should monitor blood glucose levels closely when glinides are combined with other medications.